key: cord-0883717-6ybx32l3
authors: Samaranayake, LP; Fakhruddin, KS; Ngo, H C; Bandara, MHMN; Leung, YY
title: Oro-facial Mycoses in Coronavirus Disease-2019 (COVID-19): A Systematic Review
date: 2022-03-01
journal: Int Dent J
DOI: 10.1016/j.identj.2022.02.010
sha: 0478198500b81133793b35960386a64a205c0b18
doc_id: 883717
cord_uid: 6ybx32l3

OBJECTIVES: Studies reviewing oro-facial mycoses in Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2) infection are sparse. Here we review the major oral and maxillofacial mycoses of COVID-19, the associated comorbidities, and the probable precipitating factors. METHODS: English language manuscripts published between March 2020 and October 2021 were searched using PubMed, OVID, SCOPUS, and Web of Science databases, using appropriate keywords. RESULTS: We identified 30 articles across 14 countries, which met the inclusion criteria of PRISMA guidelines. These yielded a total of 292 laboratory-confirmed COVID-19 patients, 51.4% (n=150) of whom presented with oral and maxillofacial fungal infections, mainly comprising candidosis, mucormycosis, and aspergillosis. Candidal infections were the most prevalent, present in 64% (n = 96), followed by mucormycosis, and only a single case of aspergillosis was noted. Oral and maxillofacial mycoses were predominantly seen in those with comorbidities, especially in diabetics (52.4%). Oral mucormycosis was noted in 8.6% (n=13) and mainly manifested on the hard palate. An overall event rate of oral/maxillofacial mucormycosis manifestation in COVID-19 patients with diabetes mellitus Type 1/2 was around 94% (49/52; 95% CI: 0.73%-0.89%), implying a very high association between diabetes mellitus and the latter condition. All fungal infections appeared either concurrently with COVID-19 symptoms or during the immediate recovery period. CONCLUSIONS: SARS-CoV-2 infection-related immunosuppression, steroid therapy, as well as co-morbidities such as diabetic hyperglycemia appear to be the major predisposing factors for the onset of oral and maxillofacial mycoses in COVID-19 patients across all age groups.

The coronavirus disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2 ) is associated with a wide range of opportunistic bacterial and fungal co-infections [1] . The triad of most common secondary oral fungal coinfections seen in COVID-19 is candidiasis, mucormycosis, and aspergillosis [2] .

Candida species are generally found as oral commensals, approximately one-half of the general population. They metamorphose into opportunistic pathogens when adverse conditions supervene, as in SARS-CoV-2 infection, causing both localized and systemic infections [3] .

COVID-19 itself and/or the associated contributory factors including corticosteroid therapy, lymphocytopenia, mechanical ventilator support, and other localized factors such as poor oral hygiene, xerostomia, and denture-wearing appear to favor Candida proliferation in the oral cavity [4] .

On the contrary, mucormycosis (previously called zygomycosis) is an uncommon, angioinvasive disease caused by the fungi belonging to the group of molds called Mucormycetes. The most common species that cause mucormycosis are Mucor and Rhizopus species [5] . They are rarely isolated in health from the oral cavity, and their usual transmission mode is through inhalation of fungal spores common in air and dust [6] . Recent data suggest a number of possible reasons that facilitate germination of mucorales spores in patients with SARS-CoV-2 infection.

These include hypoxic conditions, diabetes-related, and /or steroid-induced hyperglycemia and ketoacidosis, immune suppression, and several other risk mediators such as prolonged hospitalization and mechanical ventilation [7] [8] [9] . In addition, numerous reports of oral and maxillofacial mucormycosis in COVID-19 patients, particularly from the Indian sub-continent, with devastating outcomes leading to blindness are now available [10] . Recently, Singh et al [7] in a comprehensive review of oral and maxillofacial mucormycoses reported over 100 such cases in COVID-19 patients.

The last of the COVID-19 associated triad of common oral and maxillofacial mycoses is aspergillosis. Some studies note that as many as 15% of patients with COVID-19 hospitalized in an intensive care unit (ICU) develop aspergillus infection [11] . For instance, a German report observed COVID-19 associated invasive pulmonary aspergillosis in five of 19 (26.3%) patients with moderate to severe acute respiratory distress syndrome (ARDS) [12] .

Despite the relative commonality of oral and maxillofacial mycoses in COVID-19, there are no systematic reviews, to our knowledge, that specifically address the prevalence or aetiopathogenesis of these diseases, and there is a need for clinically relevant information.

Therefore, the aim of this systematic review was to identify the prevalence, aetiopathogenesis, oral and maxillofacial manifestations and management these infections either directly linked to COVID-19 per se or secondary to their treatment protocols.

Three reviewers (LPS, KSF, and HCN) executed an electronic data search using PubMed via OVID, SCOPUS, and Web of Science databases for the English language manuscripts. Published reports were accessed between March 01, 2020, and October 01, 2021, to identify either case series, observational studies, or case reports. 

The intended outcome was to review the prevalence, clinical presentation, temporality, and the likely etiology of oral and maxillofacial fungal co-infections in COVID-19 patients.

The present review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for a systematic and comprehensive approach. During the first stage of the three-staged electronic data-search and analysis, two reviewers (LPS and KSF) examined the titles and abstracts of all published relevant reports that were in line with our set inclusion criteria. Next, a full-text review of all the related articles was performed to explore the data comprehensively during stage two of the review process. A detailed analysis of the full text of the selected literature ensured that the eligibility standards were met and the reported outcomes were in accordance with the pre-set outcome measures. In addition, references of the included reports were examined as a backward search. Finally, the reviewers (LPS and KSF) extracted and assessed the data during stage two.

Upon completion of the full-text review, specific points linked to the characteristics of each individual included study were mapped and recorded. This assisted in classifying the study design, setting, intervention, and reporting jurisdiction. Besides, the sample size, assessment time, evaluation methods, and study conclusions were systematically analyzed. Finally, the third reviewer (HCN) cross-checked the data to validate its accuracy. Relevant reports with case presentations of oral and maxillofacial mucormycosis were evaluated. The frequency of occurrence of the mucormycosis manifestation among COVID-19 patients with and without comorbid diabetic conditions was analyzed with random-effects meta-analysis using a Comprehensive meta-analysis tool (CMA v.3). The identified manuscripts were listed using a bibliographic software tool, Endnote version 20 (Clarivate Analytics, USA). Summarized characteristics of the included reports are provided in (Table 1) .

During stage three of the systematic assessment of the available records, two reviewers (LPS and KSF) independently performed the quality valuation of the eligible studies employing the Joanna Briggs Institute Critical Appraisal Checklist for (i) case reports, (ii) case series, and (iii) analytical cross-sectional studies' Critical appraisal checklists' [13] . The third and fourth reviewers (YYL and MHMNB) were referred to in case of any conflict. They evaluated reports were recorded as low-risk, moderate, or high-risk, as shown in Table 1 . Any case reports or case series with a high risk of bias were omitted from the present review. All the involved reviewers discussed decisions based on the cumulative scores. The report was deemed low-risk when the 'yes' score was≥70%, moderate-risk when the score was between 50%-69%, and high-risk when the score was ≤49%.

Of the 108 full texts reviewed, 30 reported cases or case series were included in the present review, and they comprised a total of 292 COVID-19 patients, of whom only 150 had fungal manifestations (Fig. 1) . These 30 articles met the PRISMA criteria and encompassed a single descriptive observational study, six-case series, and 23 case reports.

All 150 confirmed COVID-19 patients manifested with one or more of the following predominant oral fungal infections: candidosis, aspergillosis, or mucormycosis (Table 1) . These patients were either asymptomatic or presented with mild, moderate, or severe COVID-19. In addition, a significant age diversity was noted in the cohort, ranging from three COVID-19 positive neonatal cases [15] that developed oral candida infections to adults over 75-years old, with other mycoses. Interestingly, three children aged 11 to 16 years with insulin-dependent Type 1 diabetes were noted with rhino-cerebral mucormycosis [35, 42] .

Of the cohort of patients with fungal infections, 92.6% (139/150) had comorbidities, with only a small minority without recorded comorbidity. The predominant comorbidity noted was diabetes mellitus reported in 43.3% (65/150) [21, 23-33, 35-38, 40-42] together with or without other comorbidities, such as cardiovascular diseases, renal ailments, and liver diseases. A few other patients exhibited an atopic immune condition [14] , asthma [26, 37] , and mild hypothyroidism [16, 38] .

Overall, 8.7% asymptomatic/mild and 91.3% moderate to severely affected COVID-19 patients with Candidosis, Aspergillosis, or Mucormycosis. In addition, none of the patients displayed simultaneous oral co-infection with two different mycoses (Table 1 ).

In terms of the time of appearance of the fungal infections, 95.8 % (92/96) developed candidosis with their COVID-19 symptoms and 4.2 % during the post-COVID recovery period ( Table 2) .

The time span of presentation of candidosis ranged from a few days to one month after initial COVID-19 symptom appearance. All patients with candidiasis were on either antibiotic, antiviral, and/or steroidal therapy.

As for the sites of candidal manifestations, the tongue was the most common focus of infection, followed by the soft palate, oropharynx, and the buccal/labial mucosa (Fig. 2) . Finally, all the candidal infections were managed with oral nystatin, miconazole, or systemic Fluconazole therapy ( Table 2) .

As regards oral mucormycosis, we noted 13 cases of the disease predominantly manifesting as pallor or dry palatal mucosa with dry brown secretion to brownish-black ulcerative necrotic lesions, mainly on the hard palate ( Table 2 ). Three mucormycosis patients presenting with oral lesions were simultaneously diagnosed with COVID-19 symptoms [25] [26] [27] . In addition, a number of other cases were fortuitous, incidental findings when examined for moderate/severe SARS-CoV-2 infection [42] [43] [44] .

Furthermore, all moderate/severe cases of COVID-19 with the maxillofacial manifestation of mucormycosis were hospitalized patients, mostly with comorbidities, and all were receiving systemic antibiotics, antiviral and steroidal therapies for SARS-CoV-2 infection (Table 2) . A noteworthy commonality amongst all COVID-19 patients with oral/maxillofacial mucormycosis was their uncontrolled hyperglycemic condition. Thus, the overall event rate of mucormycosis was 94 % (49/52; 95% CI: 0.73%-0.89%) among cases with known diabetic type 1/2 conditions Additionally, only a single patient presented with histopathologically confirmed oral aspergillosis

Oro-facial opportunistic mycotic co-infections are reported with increasing frequency at various stages of COVID-19. To our knowledge, the current review is the first report on the prevalence and aetiopathogenesis of the major opportunistic, mycotic co-infections specific to the oro-facial region in laboratory-confirmed COVID-19 cases. The available data clearly indicate that such co-infections in COVID-19 are due to three major fungal groups, Candida spp., Aspergillus spp., and Mucorales, a group of common zygomycotic fungi. These infections manifest with a spectrum of clinical presentations, ranging from erythematous and edematous mucosae to pseudo-membranous lesions, and on occasions, to extensive focal tissue necrosis involving the alveolar bone.

Oral candidosis due to several pathogenic candidal species is perhaps the commonest human fungal infections seen in debilitated individuals [43, 44] . C. albicans, the most common agent of oral candidiasis, as well as several non-albicans Candida species (NACS) have been reported in our cohort of COVID-19 cases, especially in hospital-bound patients [20, 23] . In general, these manifestations could be explicable in terms of diabetic ketoacidosis that promotes yeast growth and lymphocytopenia, especially the T lymphocytes, due to SARS-CoV-2 infection. Other causative factors include the use of broad-spectrum antibiotics and steroid therapy and neglected and poor oral hygiene [45] .

It is known that oral candidal infections are common amongst the `very young, the very old, and the very sick` [44] , and this aphorism has been, once again, proven to be the case in COVID-19.

For instance, candidosis was present in three full-term neonatal cases with COVID-19 infection, with no history of receiving antibiotics [15] . Characteristically, neonates exhibit immature cellular immune responses, resulting in increased susceptibility to infection [46] , and this, together with the SARS-CoV-2 infection, are the likely causes for such manifestations.

Nevertheless, more comprehensive studies are needed to better understand the oral mycoses of COVID-19 in the neonate population.

It is now known that bronchopulmonary aspergillosis is the another common opportunistic systemic infection seen in COVID-19 [47] 48]. In general, it is frequently seen in those who are immunosuppressed, and may lead to life-threatening complications [49] . A solitary case of aspergillosis with maxillary sinus invasion in an uncontrolled diabetic with severe COVID-19 was noted in our review [29] .

The disease usually ensues after inhalation of aspergillus spores, and their subsequent germination and proliferation in the bronchopulmonary system [50] . However, on occasions, the infection may manifest in nasal sinuses, the oral cavity, and the eyes [51] . The most common agent of the disease known to cause invasive oral and maxillofacial lesions is A. flavus [50] . In the absence of a robust immune response, the angioinvasive hyphal elements of Aspergillus species usually cause thrombosis leading to tissue infarction and necrosis. The other virulence traits of the fungus include the production of hemolysins, proteases, phospholipases, and the aflatoxin, gliotoxin [52] [53] [54] .

Mucorales that cause mucormycosis are common saprophytic fungi found in air, dust, and wet, organic materials [6] . They cause infection predominantly in patients with poorly controlled diabetes mellitus or those who are immunocompromised due to disease or drugs. Hence, it is not surprising the prevalence of mucormycosis has increased during the COVID-19 pandemic. Oral mucormycosis was reported in seven reviewed cases with mild to moderate SARS-CoV-2 infection, and most of them were either controlled or uncontrolled diabetics [24] [25] [26] [27] [28] [29] [30] . Their clinical presentation included malaise, facial pain, swelling, irregular black eschar, exudation of pus from the eye and nose, and low-grade fever.

As noted above mucormycosis, is the third most reported opportunistic fungal infection in patients with SARS-CoV-2 infection [55] . It has four distinct categories as rhino-cerebral, cutaneous, disseminated, gastrointestinal, or pulmonary, depending on the infected tissues [56] .

Of these, rhino cerebral mucormycosis is relevant in the current context as it affects the oral cavity, sinuses, nasal passages, and the brain. The infection usually begins in the nasal mucosa or palate and spreads via nearby vessels to the paranasal sinuses, often involving the maxillary and ethmoidal sinuses [57] . Previous literature from the pre-COVID-19 era also indicates that rhinocerebral mucormycosis affects patients with poorly controlled diabetes and immunosuppressed patients [58] . Many of the cases in our review had documented mucor invasion of cranial nerves III, IV, and VI, leading to ptosis, pupillary dilatation, proptosis, and vision loss. In addition, hematogenous spread to the cavernous sinus led to fatal cavernous sinus thrombosis in a few cases [59] [60] [61] .

In cases where mucormycosis is suspected, a prompt diagnosis and treatment are critical because of the angioinvasive nature of the fungus and its rapid systemic dissemination. A number of recent cases, particularly from the Indian sub-continent, reports of fungal invasion seeded in the maxillary sinus and progressing into maxillary alveolar bony tissues, and then the oral cavity as well as the orbits with eventual blindness of the unfortunate individual [57] . Late diagnosis of the disease with orbital invasion needs to be managed by radical surgery of the affected regions and removal of the orbital contents. 

All authors equally contributed to this work, through data computation and analysis, writing and editing the manuscript. The final approval for publication was given by all authors after perusal of the final edited version of the manuscript.

No funding from any source was received for this research compilation.

Sandron J, Hantson P, Duprez T. Intracranial brain parenchymal spread of mucormycosis through olfactory tract: a diffusion-weighted imaging-based concept. Acta Radiologica Open. 2020;9 (12) 

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents

Oral Manifestations of Coronavirus Disease 2019 (COVID-19): An Overview

Essential Microbiology for Dentistry

Oral Candidiasis and COVID-19 in Users of Removable Dentures: Is Special Oral Care Needed? Gerontology

Zygomycetes in human disease

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs

When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis

Mucormycosis and COVID-19: An epidemic within a pandemic in India

Aspergillosis Is Common Among COVID-19 Patients in the ICU

COVID-19 associated pulmonary aspergillosis

Systematic Reviews of Etiology and Risk. JBI Manual for Evidence Synthesis2020

Oral manifestations in a patient with a history of asymptomatic COVID-19: Case report

First neonates with severe acute respiratory syndrome coronavirus 2 infection in Romania: Three case reports

Oral Candidiasis in Non-Severe

Patients: Call for Antibiotic Stewardship. Oral Surg. 2020

Initial Real-Life Experience from a Designated COVID-19 Centre in Athens, Greece: a Proposed Therapeutic Algorithm

Oral symptoms and lesions in SARS-CoV-2-positive patient

Oral candidiasis as rare complication of COVID-19: A case series

Symptomatic Patients with Oral Lesions: Clinical and Histopathological Study on 123 Cases of the University Hospital Policlinic of Bari with a Purpose of a New Classification

Oral mucosal lesions in a COVID-19 patient: New signs or secondary manifestations?

Oral manifestations associated with COVID-19. Oral Dis. 2020

Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility pattern

Painful palatal lesion in a patient with COVID-19. Oral surgery, oral medicine, oral pathology and oral radiology

Rhinocerebral Mucormycosis and COVID-19

Mucormycosis with orbital compartment syndrome in a patient with COVID-19

A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19

Rhinoorbital mucormycosis during steroid therapy in COVID-19 patients: A case report

Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: A case series and a review of literature

COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors

Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19

susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations

Rhinocerebral Mucormycosis as a COVID-19-Related Complication: A Case Report from Basra City, Southern Iraq

Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19)

New-Onset Pediatric Diabetes Complicated By Diabetic Ketoacidosis and Invasive Rhinocerebral Mucormycosis With Internal Carotid Artery Occlusion

Rhino-Orbital Mucormycosis Associated With COVID-19

Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome

A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update

Title of the Article: Paranasal Mucormycosis in COVID-19 Patient

COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?

First report of COVID-19-associated rhino-orbito-cerebral mucormycosis in pediatric patients with type 1 diabetes mellitus

Oral candidosis. London: Wright

Managing patients with oral candidiasis

T cell immunity in neonates

Sinus aspergillosis and allergic fungal sinusitis

Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis

Oral mucosal fungal infections

Orofacial fungal infections. Nine pathogens that may invade during chemotherapy

Infectious granulomatous diseases of the head and neck

Invasive aspergillosis

Identifying candidate Aspergillus pathogenicity factors by annotation frequency

COVID-19-Associated Mold Infection in Critically Ill Patients, Chile. Emerging Infectious Disease journal

Novel perspectives on mucormycosis: pathophysiology, presentation, and management

Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon

Sign: An Early MR Imaging Finding of Nasal Mucormycosis

Mucormycosis of the Central Nervous System